. Author manuscript; available in PMC: 2021 Oct 4.

Published in final edited form as: Biomed Pharmacother. 2021 Oct 2;144:112276. doi: 10.1016/j.biopha.2021.112276

Table 3.

Summary of antibody treatment strategies.

Treatment	Mechanism Target	Clinical benefit?	Mortality decrease?
Convalescent Plasma	Polyclonal Abs against SARS-CoV-2	Mixed	^X
Itolizumab	mAb against CD-6- attenuates T-cell costimulation	^✓ ^*	^X ^*
Tocilizumab	mAb against IL-6 receptor	^X	^X
Etesevimab	mAb against the receptor-binding domain of the spike protein	^✓	^✓
Bamlanivimab	mAb against the receptor-binding domain of the spike protein	^✓	^✓

^✓

- The drug produced the respective column’s effect.

- The drug failed to produce the respective column’s effect. Mixed - The drug produced negative and positive outcomes.

- Clinical trials of this drug either failed to exceed 100 participants or lacked any blinding.